专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明授权

US07785821B2 Measurement of nicotinamde N-methyl transferase in diagnosis of lung cancer 有权
标题翻译：测定烟碱甲氨基转移酶诊断肺癌
公开(公告)号：US07785821B2
公开(公告)日：2010-08-31
申请号：US12362584
申请日：2009-01-30
申请人： Wolfgang Rollinger , Marie Luise Hagmann , Johann Karl , Theresa Kott , Markus Roessler , Michael Tacke
发明人： Wolfgang Rollinger , Marie Luise Hagmann , Johann Karl , Theresa Kott , Markus Roessler , Michael Tacke
IPC分类号： C12Q1/48
CPC分类号： G01N33/57423 , C12Q1/48 , G01N2333/4742 , G01N2333/91011 , G01N2333/98
摘要： The present invention relates to the assessment of lung cancer. It discloses the use of protein NNMT in the assessment of lung cancer. It also relates to a method for assessing lung cancer by measuring NNMT in vitro in a liquid sample derived from an individual. Measurement of NNMT can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
摘要翻译：本发明涉及肺癌的评估。它公开了在评估肺癌中使用蛋白质NNMT。它还涉及通过在来自个体的液体样品中体外测量NNMT来评估肺癌的方法。 NNMT的测定可以例如用于肺癌患者的早期检测或随访。

12. 发明申请

US20090263841A1 USE OF NNMT AS A MARKER FOR LUNG CANCER 有权
标题翻译：使用NNMT作为肺癌标记
公开(公告)号：US20090263841A1
公开(公告)日：2009-10-22
申请号：US12362584
申请日：2009-01-30
申请人： Wolfgang Rollinger , Marie_Luise Hagmann , Johann Karl , Theresa Kott , Markus Roessler , Michael Tacke
发明人： Wolfgang Rollinger , Marie_Luise Hagmann , Johann Karl , Theresa Kott , Markus Roessler , Michael Tacke
IPC分类号： C12Q1/48
CPC分类号： G01N33/57423 , C12Q1/48 , G01N2333/4742 , G01N2333/91011 , G01N2333/98
摘要： The present invention relates to the assessment of lung cancer. It discloses the use of protein NNMT in the assessment of lung cancer. It also relates to a method for assessing lung cancer by measuring NNMT in vitro in a liquid sample derived from an individual. Measurement of NNMT can, e.g., be used in the early detection or in the follow-up of patients with lung cancer.
摘要翻译：本发明涉及肺癌的评估。它公开了在评估肺癌中使用蛋白质NNMT。它还涉及通过在来自个体的液体样品中体外测量NNMT来评估肺癌的方法。 NNMT的测定可以例如用于肺癌患者的早期检测或随访。

13. 发明授权

US08980573B2 Method for providing diagnosis of cancer using seprase as a marker 有权
标题翻译：使用seprase作为标记提供癌症诊断的方法
公开(公告)号：US08980573B2
公开(公告)日：2015-03-17
申请号：US12791946
申请日：2010-06-02
申请人： Wolfgang Rollinger , Johann Karl , Jarema Peter Kochan , Markus Roessler , Michael Tacke
发明人： Wolfgang Rollinger , Johann Karl , Jarema Peter Kochan , Markus Roessler , Michael Tacke
IPC分类号： C12Q1/37 , G01N33/574
CPC分类号： G01N33/57423 , G01N33/57407 , G01N33/57419 , G01N33/57473 , G01N2333/96411
摘要： The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
摘要翻译：本发明涉及一种协助癌症评估的方法。它公开了使用人成纤维细胞活化蛋白（FAP / seprase）作为不同癌症类型的通用标记物。 Seprase有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。这些特定的癌症类型是例如食管，头颈癌，胃癌，胆管癌，胰腺癌，肾癌，子宫颈癌，卵巢癌，乳腺癌，膀胱癌，子宫内膜癌或前列腺癌。此外，它特别涉及通过测量所述样品中的seprase从源自个体的液体样品中评估癌症的方法。 seprase的测量可以例如用于癌症的早期检测或用于进行手术的患者的监视。

14. 发明申请

US20100240081A1 SEPRASE AS A MARKER FOR CANCER 有权
标题翻译： SEPRASE作为癌症的标记
公开(公告)号：US20100240081A1
公开(公告)日：2010-09-23
申请号：US12791946
申请日：2010-06-02
申请人： Wolfgang Rollinger , Johann Karl , Jarema Peter Kochan , Markus Roessler , Michael Tacke
发明人： Wolfgang Rollinger , Johann Karl , Jarema Peter Kochan , Markus Roessler , Michael Tacke
IPC分类号： C12Q1/48 , C12Q1/37
CPC分类号： G01N33/57423 , G01N33/57407 , G01N33/57419 , G01N33/57473 , G01N2333/96411
摘要： The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
摘要翻译：本发明涉及一种协助癌症评估的方法。它公开了使用人成纤维细胞活化蛋白（FAP / seprase）作为不同癌症类型的通用标记物。 Seprase有助于评估肺或肺癌（LC）或结肠癌，例如非小细胞肺癌（NSCLC）或结肠直肠癌（CRC），但也可能是其他特定类型的癌症。这些特定的癌症类型是例如食管，头颈癌，胃癌，胆管癌，胰腺癌，肾癌，子宫颈癌，卵巢癌，乳腺癌，膀胱癌，子宫内膜癌或前列腺癌。此外，它特别涉及通过测量所述样品中的seprase从源自个体的液体样品中评估癌症的方法。 seprase的测量可以例如用于癌症的早期检测或用于进行手术的患者的监视。

15. 发明申请

US20090286328A1 USE OF PROTEIN S100A12 AS A MARKER FOR COLORECTAL CANCER 审中-公开
标题翻译：使用蛋白S100A12作为彩色癌的标记
公开(公告)号：US20090286328A1
公开(公告)日：2009-11-19
申请号：US12264324
申请日：2008-11-04
申请人： Norbert Wild , Herbert Andres , Ursula Garczarek , Andrea Geistanger , Marie-Luise Hagmann , Johan Karl , Freidemann Krause , Michael Pfeffer , Wolfgang Rollinger , Michael Tacke , Michael Thiefolf
发明人： Norbert Wild , Herbert Andres , Ursula Garczarek , Andrea Geistanger , Marie-Luise Hagmann , Johan Karl , Freidemann Krause , Michael Pfeffer , Wolfgang Rollinger , Michael Tacke , Michael Thiefolf
IPC分类号： G01N33/566
CPC分类号： G01N33/57419 , C12Q1/6886 , G01N2333/4727 , G01N2333/805 , G01N2333/8146 , G01N2333/9121
摘要： The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
摘要翻译：本发明涉及结肠直肠癌的诊断。它公开了蛋白质S100A12在结肠直肠癌诊断中的应用。它涉及一种通过测量所述样品中的S100A12从粪便样品中诊断结直肠癌的方法。 S100A12的测定可以例如用于结肠直肠癌的早期检测或诊断。

16. 发明申请

US20080020414A1 CYFRA 21-1 AS A MARKER FOR COLORECTAL CANCER 有权
标题翻译： CYFRA 21-1作为彩色癌症的标记
公开(公告)号：US20080020414A1
公开(公告)日：2008-01-24
申请号：US11764913
申请日：2007-06-19
申请人： Johann Karl , Herbert Andres , Veit Grunert , Wolfgang Rollinger , Werner Zolg
发明人： Johann Karl , Herbert Andres , Veit Grunert , Wolfgang Rollinger , Werner Zolg
IPC分类号： G01N33/68 , C12Q1/00 , C12Q1/34 , C12Q1/48
CPC分类号： G01N33/57419 , G01N2333/4742
摘要： The present invention relates to the assessment of colorectal cancer. It discloses the use of protein CYFRA 21-1 in the assessment of colorectal cancer. It also relates to a method for assessing colorectal cancer in vitro using a liquid sample, derived from an individual by measuring CYFRA 21-1 in said sample. Measurement of CYFRA 21-1 can, e.g., be used in the early detection or in the follow-up of patients with colorectal cancer.
摘要翻译：本发明涉及结肠直肠癌的评估。它公开了蛋白质CYFRA 21-1在结肠直肠癌评估中的应用。它还涉及一种通过在所述样品中测量CYFRA 21-1从体外衍生的液体样品体外评估结肠直肠癌的方法。 CYFRA 21-1的测量可以例如用于早期检测或结直肠癌患者的随访。

17. 发明授权

US07731938B2 CYFRA 21-1 as a marker for colorectal cancer 有权
标题翻译： CYFRA 21-1作为结肠直肠癌的标志物
公开(公告)号：US07731938B2
公开(公告)日：2010-06-08
申请号：US11764913
申请日：2007-06-19
申请人： Johann Karl , Herbert Andres , Veit Peter Grunert , Wolfgang Rollinger , Werner Zolg
发明人： Johann Karl , Herbert Andres , Veit Peter Grunert , Wolfgang Rollinger , Werner Zolg
IPC分类号： A61K49/00
CPC分类号： G01N33/57419 , G01N2333/4742
摘要： The present invention relates to the assessment of colorectal cancer. It discloses the use of the CYFRA 21-1 assay in the assessment of colorectal cancer. It also relates to a method for assessing colorectal cancer in vitro using a liquid sample, derived from an individual by measuring CYFRA 21-1 in said sample. Measurement of CYFRA 21-1 can, e.g., be used in the early detection or in the follow-up of patients with colorectal cancer.
摘要翻译：本发明涉及结肠直肠癌的评估。它公开了CYFRA 21-1测定在结肠直肠癌评估中的应用。它还涉及一种通过在所述样品中测量CYFRA 21-1从体外衍生的液体样品体外评估结肠直肠癌的方法。 CYFRA 21-1的测量可以例如用于早期检测或结直肠癌患者的随访。

18. 发明申请

US20090270272A1 ASSESSING RISK OF DISEASE PROGRESSION IN RHEUMATOID ARTHRITIS PATIENTS 有权
标题翻译：评估炎症性疾病患者的疾病进展风险
公开(公告)号：US20090270272A1
公开(公告)日：2009-10-29
申请号：US12412840
申请日：2009-03-27
申请人： Johann Karl , Veit Peter Grunert , Wolfgang Rollinger , Norbert Wild
发明人： Johann Karl , Veit Peter Grunert , Wolfgang Rollinger , Norbert Wild
IPC分类号： C40B30/04 , C40B40/10
CPC分类号： G01N33/564 , G01N33/6869 , G01N33/6893 , G01N2333/4737 , G01N2333/5412 , G01N2800/102
摘要： Disclosed is an in vitro method aiding in the further assessment of patients suffering from rheumatoid arthritis. The method especially is used in assessing whether an RA patient is at risk of disease progression. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of at least C-reactive protein (CRP) and interleukin-6 and correlating the concentrations determined to the likelihood of an underlying rapidly progressing form of RA. A patient at high risk of a rapidly progressing disease might be a patient in need for treatment or if already treated in need for a different and more effective treatment. The invention also relates to the use of a marker panel comprising C-reactive protein and interleukin-6 in the assessment of a patient with rheumatoid arthritis and it teaches a protein array device and kit, respectively, for performing the method of the invention.
摘要翻译：公开了一种辅助进一步评估患有类风湿性关节炎患者的体外方法。该方法特别用于评估RA患者是否处于疾病进展的风险。该方法例如通过分析生物化学标记来实施，包括在样品中测量至少C反应蛋白（CRP）和白细胞介素-6的浓度，并将确定的浓度与RA的潜在快速进展形式的可能性相关联。患有快速进展疾病的高风险患者可能是需要治疗的患者，或者如果已经需要治疗，需要进行不同的和更有效的治疗。本发明还涉及在评估类风湿性关节炎患者中使用包含C-反应蛋白和白细胞介素-6的标记物片，并分别教导了用于实施本发明方法的蛋白质阵列装置和试剂盒。

19. 发明授权

US08058013B2 Assessing risk of disease progression in rheumatoid arthritis patients 有权
标题翻译：评估类风湿关节炎患者疾病进展的风险
公开(公告)号：US08058013B2
公开(公告)日：2011-11-15
申请号：US12412840
申请日：2009-03-27
申请人： Johann Karl , Veit Peter Grunert , Wolfgang Rollinger , Norbert Wild
发明人： Johann Karl , Veit Peter Grunert , Wolfgang Rollinger , Norbert Wild
IPC分类号： G01N33/53
CPC分类号： G01N33/564 , G01N33/6869 , G01N33/6893 , G01N2333/4737 , G01N2333/5412 , G01N2800/102
摘要： Disclosed is an in vitro method aiding in the further assessment of patients suffering from rheumatoid arthritis. The method especially is used in assessing whether an RA patient is at risk of disease progression. The method is for example practiced by analyzing biochemical markers, comprising measuring in a sample the concentration of at least C-reactive protein (CRP) and interleukin-6 and correlating the concentrations determined to the likelihood of an underlying rapidly progressing form of RA. A patient at high risk of a rapidly progressing disease might be a patient in need for treatment or if already treated in need for a different and more effective treatment. The invention also relates to the use of a marker panel comprising C-reactive protein and interleukin-6 in the assessment of a patient with rheumatoid arthritis and it teaches a protein array device and kit, respectively, for performing the method of the invention.
摘要翻译：公开了一种辅助进一步评估患有类风湿性关节炎患者的体外方法。该方法特别用于评估RA患者是否处于疾病进展的风险。该方法例如通过分析生物化学标记来实施，包括在样品中测量至少C反应蛋白（CRP）和白细胞介素-6的浓度，并将确定的浓度与RA的潜在快速进展形式的可能性相关联。患有快速进展疾病的高风险患者可能是需要治疗的患者，或者如果已经需要治疗，需要进行不同的和更有效的治疗。本发明还涉及在评估类风湿性关节炎患者中使用包含C-反应蛋白和白细胞介素-6的标记物片，并分别教导了用于实施本发明方法的蛋白质阵列装置和试剂盒。

20. 发明授权

US10815517B2 Use of DPPIV/seprase as a marker for cancer 有权
公开(公告)号：US10815517B2
公开(公告)日：2020-10-27
申请号：US13268042
申请日：2011-10-07
申请人： Magdalena Swiatek-de Lange , Johann Karl , Wolfgang Rollinger
发明人： Magdalena Swiatek-de Lange , Johann Karl , Wolfgang Rollinger
IPC分类号： C12Q1/37
摘要： Described is a method aiding in the assessment of the presence of cancer. The method uses the soluble DPPIV/seprase protein complex (DPPIV/seprase) as a universal marker of different cancer types. Measurement of DPPIV/seprase complex can, e.g., be used in the early detection or diagnosis of cancer or in the surveillance of patients who undergo surgery.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式